Resveratrol and Vitamin D Composition for ARDS Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a critical need for a medication to prevent acute respiratory distress syndrome (ARDS) and acute lung injury caused by SARS-CoV-2, as current treatments are inadequate in addressing the uncontrolled inflammation and progressive damage in COVID-19 patients, particularly in asymptomatic or mildly symptomatic individuals.

Innovation Solution

A composition comprising a pharmaceutically effective amount of a resveratrol derivative and vitamin D, combined with a pharmaceutically acceptable excipient, administered orally, locally, or via inhalation, to inhibit the NLRP3 inflammasome and reduce inflammation, thereby preventing ARDS and ALI in SARS-CoV-2 infected individuals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for COVID-19 patients, then basic respiratory support can be provided, but uncontrolled inflammation and progressive lung damage occur leading to ARDS/ALI

Engineering Contradiction:

Improveprevention of ARDS/ALIVSAvoiduncontrolled inflammation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering resveratrol and vitamin D to prevent inflammation and ARDS/ALI before they fully develop. The composition is given to infected individuals, particularly asymptomatic or mildly symptomatic patients, to proactively inhibit NLRP3 inflammasome activation and prevent the progression to severe respiratory distress syndrome

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses resveratrol and vitamin D as intermediary substances that mediate between the SARS-CoV-2 infection and the inflammatory response. These compounds act as intermediaries to modulate the immune system's reaction, specifically by inhibiting NLRP3 inflammasome activation and reducing the release of pro-inflammatory cytokines like IL-1β, thereby preventing uncontrolled inflammation

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If intubation and invasive mechanical ventilation are applied to assist breathing, then respiratory failure can be supported, but lung damage and mortality increase

Engineering Contradiction:

Improvebreathing assistanceVSAvoidlung damage

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by administering the resveratrol and vitamin D composition to counteract the development of respiratory failure and the need for invasive ventilation. By preventing inflammation and protecting lung tissue in advance, the treatment reduces the likelihood that patients will require intubation and mechanical ventilation, thereby avoiding the associated lung damage and mortality risks

Inventive Principle:

Principle #9Preliminary anti-action

3Reliability

If NLRP3 inflammasome activation occurs, then immune response to SARS-CoV-2 is initiated, but excessive cytokine release causes ARDS/ALI

Engineering Contradiction:

Improveimmune responseVSAvoidexcessive cytokine release

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the activation threshold and intensity of NLRP3 inflammasome through resveratrol and vitamin D administration. These compounds change the physiological parameters of inflammasome activation, allowing sufficient immune response to clear the virus while preventing excessive activation that would lead to cytokine storm and ARDS/ALI

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of resveratrol and vitamin D effectively prevents ARDS and ALI by suppressing the activation of the NLRP3 inflammasome and inducing autophagy, demonstrating a synergistic effect in reducing the severity of respiratory distress and lung injury in SARS-CoV-2 infected patients, as shown in preclinical models and small-scale trials.

Implementation Method 1

Resveratrol inhibits the activation step of the NLRP3 inflammasome by suppressing mitochondrial damage

Methodology Applied

Scientific EffectMitochondrial protection:

Implementation Method 2

Resveratrol also induces autophagy by activating p38

Methodology Applied

Scientific EffectAutophagy:

Implementation Method 3

Studies indicate that vitamin D has anti-inflammatory effects on chronic lung inflammation

Methodology Applied

Scientific EffectAnti-inflammatory effect:

Data Source

PatentUS20230145555A1Composition comprising resveratrol

Publication Date: 2023.05.11 GALENUS G H AG

AI summary

The invention relates to a composition comprising an effective amount of a source of a resveratrol derivative and an effective amount of a vitamin D for the prevention of an acute respiratory distress syndrome and/or an acute lung injury caused by SRS-CoV-2 and to a kit for the preparation of said composition.